Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Possibilities of Surgical Treatment of Adrenal Diseases: Comparison of Laparoscopic and Robotic-assisted Adrenalectomy-a Prospective Study
The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases. The main question it aims to answer are:
- to find the superiority of one the the surgical method mentioned above
- to compare the quality of life in patients with adrenal mass before surgery and after laparoscopic or robotic-assisted adrenalectomy.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: MUDr. Igor Hartmann Ph.D.
- Phone Number: +420588442895
- Email: Igor.Hartmann@fnol.cz
Study Contact Backup
- Name: Natalia Wiesner
- Phone Number: +420588445709
- Email: natalia.wiesner@fnol.cz
Study Locations
-
-
-
Olomouc, Czechia, 77900
- Recruiting
- University Hospital Olomouc
-
Contact:
- Igor Hartmqnn, MD, PhD
- Phone Number: +420588442895
- Email: igor.hartmann@fnol.cz
-
Principal Investigator:
- Natalia Wiesner, MD
-
Principal Investigator:
- Igor Hartmann, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Indicated adrenalectomy based on endocrinological and imaging examination.
- Written consent to participate in the study.
Exclusion Criteria:
- Simultaneous bilateral adrenalectomy.
- Adrenal expansion > 12 cm.
- Suspected malignant adrenal tumor with infiltrative growth or tumor venous thrombus according to imaging examination.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Initial examination 1
Time Frame: 1 day
|
Initial examination by a urologist and indication for the surgery.
|
1 day
|
|
Initial examination 2
Time Frame: 1 day
|
Sampling of biological material: Hemoglobin g/l
|
1 day
|
|
Surgical period 1
Time Frame: 1 day
|
Measuring the operation time in minutes.
|
1 day
|
|
Surgical period 2
Time Frame: 1 day
|
Measuring the blood loss in milliliters (ml).
|
1 day
|
|
Surgical period 3
Time Frame: 1 day
|
Record the need for conversion to open surgery.
|
1 day
|
|
Surgical period 4
Time Frame: 1 day
|
Record the surgical complications.
|
1 day
|
|
Surgical period 5
Time Frame: 1 day
|
The consumption of special surgical instruments.
|
1 day
|
|
Perioperative period 1
Time Frame: from 3- 7 days
|
Perioperatively, the length of stay in the ICU in days.
|
from 3- 7 days
|
|
Perioperative period 2
Time Frame: from 3- 7 days
|
Perioperatively, total hospitalization time in days
|
from 3- 7 days
|
|
Perioperative period 3
Time Frame: from 3- 7 days
|
Perioperatively, blood loss from the drain in mililiters (ml).
|
from 3- 7 days
|
|
Perioperative period 4
Time Frame: from 3- 7 days
|
Perioperatively, time to remove the abdominal drain in days.
|
from 3- 7 days
|
|
Perioperative period 5
Time Frame: from 3- 7 days
|
Perioperatively, need for blood substitutes.
|
from 3- 7 days
|
|
Perioperative period 6
Time Frame: from 3- 7 days
|
Perioperatively, number of forced surgical revisions.
|
from 3- 7 days
|
|
Perioperative period 7
Time Frame: from 3- 7 days
|
Perioperatively, consumption of analgesics during the hospitalization.
|
from 3- 7 days
|
|
First post-operative check-up 1
Time Frame: 1 day of examination, 14- 20 days from the surgery
|
First postoperative visit (14th to 20th postoperative day), sampling of biological material: Hemoglobin g/l
|
1 day of examination, 14- 20 days from the surgery
|
|
First post-operative check-up 2
Time Frame: 1 day of examination, 14- 20 days from the surgery
|
First postoperative visit (14th to 20th postoperative day)- an analysis of perioperative and early postoperative complications according to the Dindo Clavien classification
|
1 day of examination, 14- 20 days from the surgery
|
|
First post-operative check-up 3
Time Frame: 1 day of examination, 14- 20 days from the surgery
|
First postoperative visit (14th to 20th postoperative day)- necessary hospitalizations and operative revisions.
|
1 day of examination, 14- 20 days from the surgery
|
|
Second post-operative check-up 1
Time Frame: 1 day of examination, 85-100 days from the surgery
|
Second postoperative visit (85th to 100th postoperative day)- an analysis of late postoperative complications according to the Dindo Clavien classification.
|
1 day of examination, 85-100 days from the surgery
|
|
Second post-operative check-up 2
Time Frame: 1 day of examination, 85-100 days from the surgery
|
Second postoperative visit (85th to 100th postoperative day)- necessary hospitalizations and operative revisions
|
1 day of examination, 85-100 days from the surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: MUDr. Igor Hartmann Ph.D., Dpt. of Urology, University hospital Olomouc
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Gonadal Disorders
- Disorders of Sex Development
- Urogenital Abnormalities
- Congenital Abnormalities
- Endocrine Gland Neoplasms
- Genetic Diseases, Inborn
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Metabolism, Inborn Errors
- Neuroendocrine Tumors
- Adrenocortical Hyperfunction
- Steroid Metabolism, Inborn Errors
- Paraganglioma
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Adenoma
- Hyperplasia
- Cushing Syndrome
- Adrenal Hyperplasia, Congenital
- Adrenogenital Syndrome
- Pheochromocytoma
- Adrenocortical Carcinoma
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Adrenocortical Adenoma
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- FNOL 122/23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.